Please Wait.....
Report
Japan Cancer Pain Management Market Forecast 2024-2032
Market Report I 2024-07-16 I 139 Pages I Inkwood Research
KEY FINDINGS
The Japan cancer pain management market is expected to grow with a CAGR of 5.75% during the forecast period 2024-2032.
MARKET INSIGHTS
According to the National Institutes of Health study, Cancer Prevalence Projections in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020-2050, cancer prevalence in Japan is expected to rise significantly by 2050. The total number of cancer cases is projected to reach 3,665,900, with a possible range from 3,210,200 to 4,201,400 cases, marking a 13.1% increase from 2020. A notable aspect of this increase is the gender disparity. Female cancer survivors are projected to increase by 27.6%, while male survivors will see a modest rise of only 0.8%. Consequently, from 2040 onward, the number of female cancer survivors will surpass that of males.
By 2050, colorectal, female breast, prostate, lung, and stomach cancers are anticipated to be the most prevalent cancer types, comprising 66.4% of all cancer survivors in Japan. For males, the cancers with the highest projected absolute increases in prevalence include prostate, lung, and malignant lymphoma. In contrast, for females, the most significant increases are expected in breast, colorectal, and corpus uteri cancers. This growing cancer prevalence underscores the need for effective cancer pain management solutions.
Japan has made significant strides in managing cancer-related pain, recognizing it as an essential part of comprehensive cancer care. To enhance cancer pain treatment for patients, the country has adopted various strategies, such as setting up palliative care units and incorporating pain management protocols within oncology departments.
Moving ahead, opioid analgesics are commonly used to manage moderate to severe cancer pain. Japan follows international guidelines for opioid use, ensuring that patients receive adequate pain relief while minimizing the risks of addiction and side effects. These guidelines for cancer pain medications are part of a broader strategy to manage pain effectively. Additionally, the Japanese healthcare system promotes multidisciplinary approaches involving oncologists, palliative care specialists, nurses, and pharmacists to provide holistic pain management.
SEGMENTATION ANALYSIS
The report on the Japan cancer pain management market includes the segmentation analysis based on drug type and disease indication.
Market by Drug Type:
- Opioids
- Morphine
- Fentanyl
- Other Morphines
- Non-Opioids
- Acetaminophen
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
- Nerve Blockers
Market by Disease Indication:
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Blood Cancer
- Other Disease Indications
Inkwood Research's report on the Japan cancer pain management market provides in-depth insights as well as the market's segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis.
COMPETITIVE ANALYSIS
Key players operating in the Japan cancer pain management market include Daiichi Sankyo Company Ltd, Shionogi & Co Ltd, Hisamitsu Pharmaceutical Co Ltd, Pfizer, Teva Pharmaceutical Industries, Mundipharma International, etc.
Pfizer Inc is a biopharmaceutical firm that develops healthcare solutions ranging from disease prevention to the treatment of chronic ailments and rare disorders. The company's three main business segments are pharmaceuticals, vaccines, and consumer healthcare. Pfizer has a substantial presence in North America, Europe, Asia, Latin America, and other locations. Its global headquarters are in New York City, United States.
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT - JAPAN
2.3. COUNTRY ANALYSIS - JAPAN
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.5.1. IMPACT OF COVID-19 ON THE JAPAN CANCER PAIN MANAGEMENT MARKET
2.6. MAJOR MARKET FINDINGS
2.6.1. INNOVATIONS IN PALLIATIVE CARE
2.6.2. SURGE IN PERSONALIZED MEDICINE APPROACHES
2.6.3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING PREVALENCE OF CANCER IN JAPAN
3.1.2. SURGE IN GERIATRIC POPULATION
3.1.3. CONTINUOUS EDUCATION AND KNOWLEDGE DISSEMINATION IN PAIN MANAGEMENT
3.2. KEY RESTRAINTS
3.2.1. REGULATORY CHALLENGES AND APPROVAL DELAYS
3.2.2. HIGH COST OF TREATMENT
3.2.3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN JAPAN
4.1.2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
4.1.3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES
4.2. PESTLE ANALYSIS
4.2.1. POLITICAL
4.2.2. ECONOMICAL
4.2.3. SOCIAL
4.2.4. TECHNOLOGICAL
4.2.5. LEGAL
4.2.6. ENVIRONMENTAL
4.3. PORTER'S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTIONS
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING - JAPAN
4.5. VALUE CHAIN ANALYSIS
4.5.1. RESEARCH & DEVELOPMENT
4.5.2. REGULATORY APPROVAL
4.5.3. MANUFACTURING
4.5.4. DISTRIBUTION
4.5.5. END-USERS
5. MARKET BY DRUG TYPE
5.1. OPIOIDS
5.2. MORPHINE
5.2.1. FENTANYL
5.2.2. OTHER MORPHINES
5.3. NON-OPIOIDS
5.4. ACETAMINOPHEN
5.5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6. NERVE BLOCKERS
6. MARKET BY DISEASE INDICATION
6.1. LUNG CANCER
6.2. COLORECTAL CANCER
6.3. BREAST CANCER
6.4. PROSTATE CANCER
6.5. BLOOD CANCER
6.6. OTHER DISEASE INDICATIONS
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. DAIICHI SANKYO COMPANY LIMITED
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCTS
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. SHIONOGI & CO LTD
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCTS
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. HISAMITSU PHARMACEUTICAL CO LTD
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCTS
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. PFIZER
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCTS
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. TEVA PHARMACEUTICAL INDUSTRIES
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCTS
7.2.5.3. STRENGTHS & CHALLENGES
7.2.6. MUNDIPHARMA INTERNATIONAL
7.2.6.1. COMPANY OVERVIEW
7.2.6.2. PRODUCTS
7.2.6.3. STRENGTHS & CHALLENGES
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - CANCER PAIN MANAGEMENT
TABLE 2: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: JAPAN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: JAPAN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: JAPAN CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 8: LIST OF MERGERS & ACQUISITIONS
TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING - JAPAN
FIGURE 4: VALUE CHAIN ANALYSIS
FIGURE 5: JAPAN CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2023
FIGURE 6: JAPAN CANCER PAIN MANAGEMENT MARKET, BY OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 7: JAPAN CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, 2024-2032 (IN $ MILLION)
FIGURE 8: JAPAN CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY MORPHINE, IN 2023
FIGURE 9: JAPAN CANCER PAIN MANAGEMENT MARKET, BY FENTANYL, 2024-2032 (IN $ MILLION)
FIGURE 10: JAPAN CANCER PAIN MANAGEMENT MARKET, BY OTHER MORPHINES, 2024-2032 (IN $ MILLION)
FIGURE 11: JAPAN CANCER PAIN MANAGEMENT MARKET, BY NON-OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 12: JAPAN CANCER PAIN MANAGEMENT MARKET, BY ACETAMINOPHEN, 2024-2032 (IN $ MILLION)
FIGURE 13: JAPAN CANCER PAIN MANAGEMENT MARKET, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2024-2032 (IN $ MILLION)
FIGURE 14: JAPAN CANCER PAIN MANAGEMENT MARKET, BY NERVE BLOCKERS, 2024-2032 (IN $ MILLION)
FIGURE 15: JAPAN CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DISEASE INDICATION, IN 2023
FIGURE 16: JAPAN CANCER PAIN MANAGEMENT MARKET, BY LUNG CANCER, 2024-2032 (IN $ MILLION)
FIGURE 17: JAPAN CANCER PAIN MANAGEMENT MARKET, BY COLORECTAL CANCER, 2024-2032 (IN $ MILLION)
FIGURE 18: JAPAN CANCER PAIN MANAGEMENT MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)
FIGURE 19: JAPAN CANCER PAIN MANAGEMENT MARKET, BY PROSTATE CANCER, 2024-2032 (IN $ MILLION)
FIGURE 20: JAPAN CANCER PAIN MANAGEMENT MARKET, BY BLOOD CANCER, 2024-2032 (IN $ MILLION)
FIGURE 21: JAPAN CANCER PAIN MANAGEMENT MARKET, BY OTHER DISEASE INDICATIONS, 2024-2032 (IN $ MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security